摘要
目的 :观察重组人促红细胞生成素 (r HuEPO) 1万U ,qw ,在改善腹透患者贫血的有效性及其药物不良反应。方法 :从上海 3家医院的腹透患者中选择透析稳定的贫血患者 4 8例 ,给予r HuEPO 1万U ,sc ,qw ,疗程 6mo ,期间如Hb快速上升至 10 0g·L-1,减量至每 2wk 1次或更少。分别于给药前和给药后wk 2、4、8、12、16、2 0、2 4 ,测定Hb、RBC和血细胞比容 (HCT)观察疗效。结果 :①治疗贫血的总有效率达 89 6 % ,其中显效率 75 % ,Hb从治疗后wk 4起显著上升 (P =0 0 0 2 1) ;② 7例患者因Hb在wk 8达较高水平〔Hb(94 9± 16 9)g·L-1,HCT(2 8 2± 5 1) %〕 ,用药剂量维持在每 10～ 14d 1万U ,16wk后复查发现HCT仍维持在 (2 8 6± 3 8) % (P >0 0 5 ) ;③平均动脉压总体稳定 (从用药前 99 8mmHg至治疗 2 4wk时 10 1 9mmHg,P >0 0 5 )。 1例患者因头痛、BP上升而退出研究。结论 :r HuEPO 1万U ,qw ,能明显改善腹膜透析患者的贫血 ,使用安全。
AIM: To observe the efficacy and safety of high-dosed recombinant human erythropoietin (r-HuEPO) on anemia in peritoneal dialysis patients. METHODS: Forty-eight CAPD patients were enrolled from 3 different hospitals in Shanghai. Patients received 10 000 U of r-HuEPO, qw, sc, and followe-up for 6 mo. If hemoglobin (Hb) increase very fastly, the dose was reduced to 10 000 U every other week or even less. RESULTS: ① Hb increase significantly and clinical efficiency ratio was 89.6% at the end of study. Statistical significance was appeared at wk 4 (P=0.002 1). ②7 of 48 patients were prescribed received 10 000 U EPO sc q 10-14 d at wk 8 because of higher level of Hb and HCT 〔Hb: (94.9±16.9) g·L -1, HCT:(28.2±561)%〕. After following-up for 16 wk, HCT was maintained at (28.6±3.8)%(P>0.05). ③ Average arterial pressure was stable during 6 mo 〔from 99.8 to 101.9 mmHg, (1 mmHg=0.133 kPa) P>0.05〕. Only one patient dropped out because of hypertension and headache. CONCLUSION: The use of high-dosed r-HuEPO can yield an efficient outcome in improving renal animia in HD patients. Some PD patients whose anemia have improved can prolong the interval of injection such as 10 to 14 days.
出处
《中国临床药学杂志》
CAS
2004年第5期261-264,共4页
Chinese Journal of Clinical Pharmacy
